Secreting pituitary adenomas are tumors for which few treatment options are available,
including surgical treatment and management of hormonal imbalance due to altered …

CONCLUSION: APA is a tumor with frequent recurrence and a short median expected length
of survival. Here, we demonstrate the utility of immunotherapy in a single case report of APA …

Background Pituitary carcinomas are rare but aggressive and require maximally coordinated
multimodal therapies. For refractory tumors, unresponsive to temozolomide (TMZ) …

Context Aggressive pituitary tumors that have progressed following temozolomide have
limited treatment options. Peptide receptor radionuclide therapy and immunotherapy may …

Pituitary carcinoma is an aggressive tumor characterized by metastatic spread beyond the
sellar region. Symptoms can be debilitating due to hormonal excess and survival is poor …

Context Pituitary carcinoma is a rare and aggressive malignancy with a poor prognosis and
few effective treatment options. Case A 35-year-old woman presented with an aggressive …

Immune checkpoint inhibitors have improved survival in numerous advanced malignancies,
but are associated with a number of immune-related adverse events, including …

After temozolomide failure, no evidence-based treatment option is currently available for
aggressive pituitary tumors (APTs) and pituitary carcinomas (PCs). Moreover, once …

Aggressive pituitary tumors (APTs) are associated with significant morbidity and mortality,
and effective treatment options are limited. Immune checkpoint inhibitors (ICIs) have …

Once temozolomide has failed, no other treatment is recommended for pituitary carcinomas
and aggressive pituitary tumors. Recently, the use of immune checkpoint inhibitors (ICIs) has …